254 related articles for article (PubMed ID: 28242122)
1. Apremilast, beyond psoriasis as a therapeutic target.
Ruiz-Villaverde R; Bueno-Rodriguez A; Tercedor-Sánchez J
Med Clin (Barc); 2017 Jul; 149(1):42-43. PubMed ID: 28242122
[No Abstract] [Full Text] [Related]
2. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.
Chiricozzi A; Caposiena D; Garofalo V; Cannizzaro MV; Chimenti S; Saraceno R
Expert Rev Clin Immunol; 2016; 12(3):237-49. PubMed ID: 26692125
[TBL] [Abstract][Full Text] [Related]
3. Apremilast as therapeutic option in a HIV positive patient with severe psoriasis.
Sacchelli L; Patrizi A; Ferrara F; Bardazzi F
Dermatol Ther; 2018 Nov; 31(6):e12719. PubMed ID: 30358044
[No Abstract] [Full Text] [Related]
4. Synergistic cytokine effects as apremilast response predictors in patients with psoriasis.
Garcet S; Nograles K; Correa da Rosa J; Schafer PH; Krueger JG
J Allergy Clin Immunol; 2018 Sep; 142(3):1010-1013.e6. PubMed ID: 29936103
[No Abstract] [Full Text] [Related]
5. Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast.
Fattore D; Annunziata MC; Panariello L; Marasca C; Fabbrocini G
Eur J Cancer; 2019 Mar; 110():107-109. PubMed ID: 30785013
[No Abstract] [Full Text] [Related]
6. Apremilast for a psoriasis patient with HIV and hepatitis C.
Reddy SP; Shah VV; Wu JJ
J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):e481-e482. PubMed ID: 28449227
[No Abstract] [Full Text] [Related]
7. Rapid improvement of nail matrix psoriasis with apremilast: clinical and ultrasonographic assessment.
Muñoz-Santos C; Sola-Ortigosa J; Guilabert A
Clin Exp Dermatol; 2018 Jul; 43(5):606-607. PubMed ID: 29453771
[No Abstract] [Full Text] [Related]
8. A case of anti-laminin γ1 (p200) pemphigoid with psoriasis vulgaris successfully treated with apremilast.
Waki Y; Kamiya K; Komine M; Maekawa T; Murata S; Ishii N; Hashimoto T; Ohtsuki M
Eur J Dermatol; 2018 Jun; 28(3):413-414. PubMed ID: 29619999
[No Abstract] [Full Text] [Related]
9. Apremilast for the management of moderate to severe plaque psoriasis.
Vangipuram R; Alikhan A
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
[TBL] [Abstract][Full Text] [Related]
10. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.
Nast A; Spuls PI; van der Kraaij G; Gisondi P; Paul C; Ormerod AD; Saiag P; Smith CH; Dauden E; de Jong EM; Feist E; Jobling R; Maccarone M; Mrowietz U; Papp KA; Reich K; Rosumeck S; Talme T; Thio HB; van de Kerkhof P; Werner RN; Dressler C
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):1951-1963. PubMed ID: 28895202
[No Abstract] [Full Text] [Related]
11. ▼ Apremilast for psoriasis and psoriatic arthritis.
Drug Ther Bull; 2015 Sep; 53(9):105-8. PubMed ID: 26358317
[TBL] [Abstract][Full Text] [Related]
12. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis.
Danesh MJ; Beroukhim K; Nguyen C; Levin E; Koo J
Dermatol Online J; 2015 Jun; 21(6):. PubMed ID: 26158370
[TBL] [Abstract][Full Text] [Related]
13. Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis.
Wong TH; Sinclair S; Smith B; Fraser C; Morton CA
Clin Exp Dermatol; 2017 Aug; 42(6):675-676. PubMed ID: 28621002
[No Abstract] [Full Text] [Related]
14. Effective treatment of nail psoriasis with apremilast: report of two cases and review of the literature.
Magdaleno-Tapial J; Valenzuela-Oñate C; Ortiz-Salvador JM; Subiabre-Ferrer D; Hernández-Bel P
Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677839
[TBL] [Abstract][Full Text] [Related]
15. A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study.
Ighani A; Georgakopoulos JR; Walsh S; Shear NH; Yeung J
J Am Acad Dermatol; 2018 Mar; 78(3):623-626. PubMed ID: 28989112
[No Abstract] [Full Text] [Related]
16. Psoriasis and chronic myeloid leukemia: treatment with Apremilast.
Vico-Alonso C; Sánchez-Velázquez A; Pinilla-Martin B; Andrés-Lencina JJ; Aragón-Miguel R; Calleja-Algarra A; Rivera-Díaz R
Int J Dermatol; 2020 Apr; 59(4):e102-e103. PubMed ID: 31347142
[No Abstract] [Full Text] [Related]
17. Apremilast in a patient with psoriasis and mantle cell lymphoma under maintenance treatment with rituximab.
Peitsch WK
J Dtsch Dermatol Ges; 2019 Mar; 17(3):330-332. PubMed ID: 30775841
[No Abstract] [Full Text] [Related]
18. Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis.
Sacchelli L; Patrizi A; Loi C; Bardazzi F
Clin Exp Dermatol; 2019 Oct; 44(7):e243-e244. PubMed ID: 31055844
[No Abstract] [Full Text] [Related]
19. Pembrolizumab-induced psoriasis vulgaris successfully treated with apremilast.
Takama H; Shibata T; Ando Y; Yanagishita T; Ohshima Y; Akiyama M; Watanabe D
Eur J Dermatol; 2020 Apr; 30(2):188-190. PubMed ID: 32538362
[No Abstract] [Full Text] [Related]
20. Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.
Dressler C; Rosumeck S; Werner RN; van der Kraaij G; van Lumig P; Wakkee M; Spuls P; Nast A
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):1964-1977. PubMed ID: 28944515
[No Abstract] [Full Text] [Related]
[Next] [New Search]
